Vancomycin is one of the oldest antibiotics still in hospital use, and it is built on a peptide backbone. This guide covers its structure, how it works, its FDA-labeled uses, the key clinical evidence and its label warnings. Sources were checked on November 17, 2026.
Quick answer: Vancomycin is a prescription glycopeptide antibiotic. Its labels list serious infections caused by methicillin-resistant staphylococci and other gram-positive bacteria, plus Clostridioides difficile-associated diarrhea for the Vancocin brand. Kidney injury, hearing loss and allergic or flushing reactions are among its label warnings. It has no boxed warning.
Vitrapep does not sell vancomycin; this page is a reference summary of published research and regulatory information.
What is vancomycin?
Vancomycin is a natural product antibiotic. The Baxter label describes it as “a tricyclic glycopeptide antibacterial derived from Amycolatopsis orientalis (formerly Nocardia orientalis)” (Baxter label, 2025).
Why call it a peptide? Its core is a short chain of amino acids, cross-linked into rings and decorated with sugars. The NCI Thesaurus, quoted in PubChem, calls it “a branched tricyclic glycosylated peptide.” The bacterium builds it with enzymes rather than ribosomes, which makes it a nonribosomal peptide. PubChem lists the formula as C66H75Cl2N9O24 and the molecular weight as 1,449.2 g/mol (PubChem CID 14969). For how peptides are grouped, see our overview of types of peptides.
Vancomycin labels from Baxter and from Hikma (sold as Tyzavan) give an initial U.S. approval year of 1958. The Vancocin brand label, now held by ANI Pharmaceuticals, lists 1986 for that product. A 2006 history review notes that vancomycin had been in clinical use for more than 50 years by then (Levine, 2006).
Vancomycin: key facts
| Fact | Detail |
|---|---|
| Structure type | Tricyclic glycopeptide (glycosylated nonribosomal peptide) |
| Class | Glycopeptide antibacterial |
| Molecular formula | C66H75Cl2N9O24 |
| Molecular weight | 1,449.2 g/mol |
| First FDA approval | 1958 (initial U.S. approval stated on current labels) |
| Brand names (US) | Vancocin, Firvanq, Tyzavan; many generic labels |
How does vancomycin work?
Bacteria wrap themselves in a cell wall made of peptidoglycan. They build it from small precursor units that end in two linked amino acids, D-alanyl-D-alanine. Vancomycin “binds tightly to the D-alanyl-D-alanine portion of cell wall precursors,” in the NCI Thesaurus wording quoted by PubChem. That blocks the next building steps, so the wall cannot be finished.
The labels put it simply. “The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis.” They add that vancomycin “alters bacterial-cell-membrane permeability and RNA synthesis” (Baxter label, 2025). The Baxter label also states there is no cross-resistance between vancomycin and other antibacterials.
What is vancomycin approved for?
Different vancomycin products carry different approved uses. The Baxter label lists these indications, each tied to susceptible bacteria:
- septicemia;
- infective endocarditis;
- skin and skin structure infections;
- bone infections; and
- lower respiratory tract infections.
Most of these name methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci. They also cover methicillin-susceptible staphylococci in patients allergic to penicillin. The endocarditis indication adds streptococci, enterococci and Corynebacterium. Tyzavan’s label lists the same five headings (Tyzavan label, 2026).
The Vancocin label is different. It states that “VANCOCIN is indicated for the treatment of Clostridioides difficile-associated diarrhea.” It also covers S. aureus enterocolitis, including methicillin-resistant strains, in adults and children under 18 (Vancocin label, 2025). Its limitations section says this product is not effective for other types of infections.
What does the key evidence show?
Vancomycin reached the market long before modern trial standards, so much of its evidence comes from later studies and reviews. A 2006 review in Clinical Infectious Diseases traces its history and its growing use as MRSA spread (Levine, 2006).
The clearest modern data come from two multinational randomized controlled trials in adults with C. difficile infection, pooled in one 2014 report. Patients were assigned 2:1:1 to tolevamer, metronidazole or vancomycin. The pooled analysis included 563, 289 and 266 patients. The primary outcome was clinical success: diarrhea resolved without severe abdominal discomfort.
Clinical success was 44.2% with tolevamer, 72.7% with metronidazole and 81.1% with vancomycin. Tolevamer was inferior to both antibiotics (P < .001). Metronidazole was inferior to vancomycin (P = .02). In severe disease, success was 66.3% with metronidazole and 78.5% with vancomycin, a difference that was not significant (P = .059). These are human data (Johnson et al., 2014).
For MRSA bloodstream infections, vancomycin was the main comparator in the pivotal daptomycin trial. Our daptomycin guide covers that study.
What side effects does the label list?
Vancomycin labels carry no boxed warning. The Baxter label’s warnings cover severe allergic and flushing reactions, nephrotoxicity, ototoxicity, severe skin reactions, C. difficile-associated diarrhea and neutropenia. Its highlights name anaphylaxis, the “vancomycin infusion reaction,” acute kidney injury and hearing loss among the most common adverse reactions.
The same label warns of hemorrhagic occlusive retinal vasculitis, including permanent loss of vision, in patients who received vancomycin in the eye. The Vancocin label lists nausea (17%), abdominal pain (15%) and hypokalemia (13%) as its most common adverse reactions.
Resistance is the other concern. CDC estimates that vancomycin-resistant enterococci (VRE) caused 54,500 infections among hospitalized U.S. patients in 2017, with 5,400 deaths (CDC, 2024). CDC also tracks vancomycin-intermediate and vancomycin-resistant S. aureus (CDC).
What is vancomycin’s regulatory status, and how is it used in research?
Vancomycin is a prescription drug in the United States. DailyMed lists dozens of current labels from brand and generic makers, including Vancocin, Firvanq and Tyzavan. Several labels were updated in 2026. WHO’s 2024 list of medically important antimicrobials places glycopeptides, including vancomycin, among drugs authorized for use in humans only (WHO, 2024).
Vancomycin also has a long role in the microbiology lab. CDC guidance on gonorrhea testing describes selective culture media, such as Thayer-Martin or Martin-Lewis, that contain vancomycin, colistin and an antifungal agent. These agents suppress other bacteria and fungi so that Neisseria gonorrhoeae can grow (CDC, 2002). Colistin is covered in our polymyxin B and colistin guide.
Frequently asked questions about vancomycin
Is vancomycin a peptide?
Yes. It is a glycopeptide: a short, ring-linked chain of amino acids with sugars attached. Bacteria make it with enzymes, not ribosomes, so it is a nonribosomal peptide.
When was vancomycin first approved by the FDA?
Current vancomycin labels from Baxter and Hikma state an initial U.S. approval year of 1958.
What bacteria does vancomycin target?
Its labeled uses name gram-positive bacteria such as MRSA, coagulase-negative staphylococci, streptococci, enterococci and C. difficile. Each indication applies only to susceptible strains.
What is VRE?
VRE are enterococci that resist vancomycin. CDC estimated 54,500 VRE infections in hospitalized U.S. patients in 2017.
Does vancomycin have a boxed warning?
No. The labels we read have no boxed warning. Their warnings include kidney injury, hearing loss, severe skin reactions and C. difficile-associated diarrhea.
What to know now
- Structure: tricyclic glycopeptide; C66H75Cl2N9O24; 1,449.2 g/mol.
- Approval: labels state initial U.S. approval in 1958; prescription only.
- Mechanism: binds D-Ala-D-Ala ends of cell-wall precursors and blocks cell-wall synthesis.
- Evidence: in pooled human trials, vancomycin beat metronidazole for C. difficile clinical success (81.1% vs 72.7%).
- Safety: no boxed warning; kidney, hearing and allergic reactions lead the label warnings.
- Resistance: CDC estimated 54,500 VRE infections in hospitalized U.S. patients in 2017.
What we’re watching
Label revisions on DailyMed, where the Tyzavan label was revised in August 2026 and several generic labels changed this year. CDC surveillance updates on VRE and on vancomycin-resistant S. aureus. Related guides: daptomycin and bacitracin.